Clarity behind
the biotech story.
Biotech is complex. The evidence should be clear. We examine clinical trials, scientific claims, and company disclosures to help you see the whole picture.
Evidence-led research. Independent by design.
From claim
to clarity.
research process
primary evidence
structured report
Guided by independence.
A closer look.
A clearer perspective.
Small biotech companies operate in highly technical environments where investors may struggle to independently evaluate scientific claims. Promotional narratives travel fast; primary-source evidence moves slowly.
Pharma Investgator analyzes primary-source evidence — trial registries, filings, publications, and data — rather than relying on promotional presentations. Every material conclusion we publish is tied to a document you can inspect yourself.
Excerpt — Investor Presentation, Slide 14
“Our Phase 2 program demonstrated strong efficacy trends across key measures, with a robust response observed in biomarker-positive patients…”
“We remain on track for a pivotal readout in H2, supporting our peak-sales assumptions.”
What We Investigate
Six evidence domains. One standard: claims must be supported by primary-source documentation.
Clinical Trials
Registered protocols vs. reported outcomes. Endpoint history, design changes, enrollment, timelines, and statistical results reconstructed from primary records.
Scientific Claims
Mechanism-of-action assertions, publication quality, preclinical-to-clinical translation, and whether the science supports the story being sold.
SEC Disclosures
Filings, risk factors, and MD&A language compared against clinical reality. Inconsistencies between disclosure and evidence are flagged and documented.
Management Statements
Earnings calls, CEO interviews, and press-release quotes verified against independent evidence. Promotional language is tested, not taken at face value.
Regulatory Risk
FDA correspondence, pathway assumptions, trial holds, and approval probability. Regulatory history is reconstructed before market narratives are trusted.
Commercial Assumptions
Addressable population, competition, standard of care, pricing, reimbursement, and manufacturing feasibility — tested against clinical evidence.
Good research follows
a clear process.
Six careful steps, from the first question to a documented conclusion.
Identify the Claim
A specific, testable statement is extracted from an investor deck, earnings call, press release, or filing — quoted verbatim, with source and date.
Locate the Primary Evidence
We go to the primary record: trial registries, FDA documents, publications, patents, and filings. Secondary reporting is never the basis for a conclusion.
Reconstruct the Clinical Story
Endpoint history, protocol amendments, enrollment, timelines, and design changes are rebuilt chronologically to reveal what changed — and when.
Analyze the Statistics
Significance vs. clinical relevance. Sample size, power, missing data, patient selection, and subgroup analyses are examined without deference to the press release.
Compare Disclosure vs. Evidence
What the company told investors is set against what the data shows. Material inconsistencies are documented — in careful, evidence-based language.
Publish the Findings
Every report states what supports the company, what contradicts it, and what remains unresolved — with a full source appendix. Trust the evidence, not the promotion.
Investigations Index
A searchable database of biotech investigations. Entries below are fictional samples for design demonstration.
| Company | Ticker | Drug | Phase | Status | Key Red Flag | Report |
|---|---|---|---|---|---|---|
| ApexNova Therapeutics | APXV | ANX-204 | Phase 2 | Complete | Primary endpoint missed; subgroup-driven claims | High Risk |
| Curiative Pharma | CURX | CUR-319 | Phase 3 | Complete | Registry endpoints differ from publication endpoints | Critical Red Flags |
| Helixor Bio | HLXB | HLX-117 | Phase 1/2 | Complete | Small n; unblinded efficacy readout | Elevated Risk |
| Meridian Cell Sciences | MRDC | MRC-88 | Phase 2 | Monitoring | Manufacturing yield assumptions unverified | Watch |
| Novaris Gene | NVGN | NVG-7 | IND | Complete | No material discrepancies identified in public data | Low Concern |
Case File: ApexNova Therapeutics
A worked example of a Pharma Investgator claim-verification investigation, from company claim to evidence-based verdict.
Breakthrough Phase 2 efficacy.
Who We Work With
Investigative research for professionals who need the evidence behind the story — on either side of a trade or dispute.
Institutional Investors
Portfolio-level scientific due diligence before positions are sized.
Hedge Funds
Long and short theses tested against primary-source clinical evidence.
Family Offices
Independent verification for direct and fund-level biotech exposure.
Law Firms
Scientific research support for securities and pharmaceutical litigation.
Private Investors
Claim verification before buying, shorting, or participating in financings.
Journalists
Documented, sourced scientific analysis for investigative reporting.
Biotech Executives
External stress-testing of internal programs before the market does it.
Due-Diligence Teams
Specialist clinical, statistical, and regulatory research capacity on demand.
Request an Investigation
Submit a company, a ticker, or a specific claim. We respond with a scoped investigation plan — research and due diligence, not investment advice.